{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:27:09Z","timestamp":1740108429256,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T00:00:00Z","timestamp":1705017600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T00:00:00Z","timestamp":1705017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum D\u00fcsseldorf. Anstalt \u00f6ffentlichen Rechts"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Legal Med"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Synthetic cannabinoids become increasingly popular as a supposedly safe and legal alternative to cannabis. In order to circumvent the German New Psychoactive Substances Law, producers of so-called herbal mixtures rapidly design new substances with structural alterations that are not covered by the law. Acting as full agonists not only at the cannabinoid receptors 1 and 2, synthetic cannabinoids might have not only desired mental but also serious physical adverse effects. However, knowledge of adverse effects of specific substances is sparse and incomplete. This also accounts for 5F-Cumyl-PEGACLONE, a synthetic cannabinoid, which has been detected regularly in Germany in recent years. By using an animal model, the isolated perfused Langendorff heart, the study at hand aimed on finding out more about possible cardiovascular adverse effects of 5F-Cumyl-PEGACLONE. Hearts of male Wistar rats, which were excised postmortem, were exposed to two different concentrations of 5F-Cumyl-PEGACLONE: 13 hearts were exposed to 50\u00a0ng\/ml and 12 hearts were exposed to 100\u00a0ng\/ml. Thirteen control hearts were merely exposed to an additional amount of buffer solution. Functional parameters heart rate, minimal and maximum left ventricular pressure and coronary flow were documented at pre-defined time points during and after the administration of 5F-Cumyl-PEGACLONE\/additional buffer solution. Electrocardiograms (ECGs) were documented throughout the experiments and evaluated afterwards. Kruskal\u2013Wallis analysis was performed for each functional parameter as well as for the\u00a0duration of the QRS complexes and the duration of RR intervals as derived from the ECGs. Furthermore, a multivariate analysis, comprising all functional and ECG parameters, was performed. Kruskal\u2013Wallis analysis revealed only single significant <jats:italic>p<\/jats:italic>-values for QRS duration and minimum left ventricular pressure\u00a0that did not\u00a0pass a Bonferroni test. The results of the multivariate approach were also comparably homogeneous, but still the model correctly recognized hearts exposed to 100\u00a0ng\/ml of 5F-Cumyl-PEGACLONE more often than hearts exposed to the low concentration of 5F-Cumyl-PEGACLONE or additional buffer solution. Evaluation of the ECGs presented single cases of ST depression and QT prolongation. Though certainly not unambiguous, these findings support the assumption that 5F-Cumyl-PEGACLONE can cause severe, if not lethal, cardiac adverse effects like arrhythmias or myocardial infarctions especially if it is consumed in combination with other drugs like alcohol or if the consumer suffers from pre-existing heart diseases.<\/jats:p>","DOI":"10.1007\/s00414-023-03146-3","type":"journal-article","created":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T10:02:34Z","timestamp":1705053754000},"page":"823-831","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiac effects of 5F-Cumyl-PEGACLONE"],"prefix":"10.1007","volume":"138","author":[{"given":"Nicole","family":"Esdar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelyn","family":"Pawlik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon B.","family":"Eickhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annika","family":"Raupach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Ritz-Timme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8876-0164","authenticated-orcid":false,"given":"Felix","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,12]]},"reference":[{"key":"3146_CR1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/MAJ.0000000000000466","volume":"350","author":"B Mills","year":"2015","unstructured":"Mills B, Yepes A, Nugent K (2015) Synthetic cannabinoids. Am J Med Sci 350:59\u201362. https:\/\/doi.org\/10.1097\/MAJ.0000000000000466","journal-title":"Am J Med Sci"},{"key":"3146_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.fsisyn.2020.11.003","volume":"3","author":"JNA Tettey","year":"2021","unstructured":"Tettey JNA, Crean C, Rodrigues J et al (2021) United Nations Office on Drugs and Crime: recommended methods for the identification and analysis of synthetic cannabinoid receptor agonists in seized materials. Forensic Sci Int Synerg 3:100129. https:\/\/doi.org\/10.1016\/j.fsisyn.2020.11.003","journal-title":"Forensic Sci Int Synerg"},{"key":"3146_CR3","doi-asserted-by":"publisher","first-page":"117822181770173","DOI":"10.1177\/1178221817701739","volume":"11","author":"TW Lefever","year":"2017","unstructured":"Lefever TW, Marusich JA, Thomas BF et al (2017) Vaping synthetic cannabinoids: a novel preclinical model of E-cigarette use in mice. Subst Abuse 11:1178221817701739. https:\/\/doi.org\/10.1177\/1178221817701739","journal-title":"Subst Abuse"},{"key":"3146_CR4","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/dta.2752","volume":"12","author":"RM Alam","year":"2020","unstructured":"Alam RM, Keating JJ (2020) Adding more \u201cspice\u201d to the pot: a review of the chemistry and pharmacology of newly emerging heterocyclic synthetic cannabinoid receptor agonists. Drug Test Anal 12:297\u2013315. https:\/\/doi.org\/10.1002\/dta.2752","journal-title":"Drug Test Anal"},{"key":"3146_CR5","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/cpt.563","volume":"101","author":"R Le Boisselier","year":"2017","unstructured":"Le Boisselier R, Alexandre J, Lelong-Boulouard V, Debruyne D (2017) Focus on cannabinoids and synthetic cannabinoids. Clin Pharmacol Ther 101:220\u2013229. https:\/\/doi.org\/10.1002\/cpt.563","journal-title":"Clin Pharmacol Ther"},{"key":"3146_CR6","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/sj.bjp.0705725","volume":"142","author":"MD Randall","year":"2004","unstructured":"Randall MD, Kendall DA, O\u2019Sullivan S (2004) The complexities of the cardiovascular actions of cannabinoids. Br J Pharmacol 142:20\u201326. https:\/\/doi.org\/10.1038\/sj.bjp.0705725","journal-title":"Br J Pharmacol"},{"key":"3146_CR7","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.forsciint.2009.06.008","volume":"191","author":"R Lindigkeit","year":"2009","unstructured":"Lindigkeit R, Boehme A, Eiserloh I et al (2009) Spice: a never ending story? Forensic Sci Int 191:58\u201363. https:\/\/doi.org\/10.1016\/j.forsciint.2009.06.008","journal-title":"Forensic Sci Int"},{"key":"3146_CR8","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s11419-014-0247-4","volume":"33","author":"B Moosmann","year":"2014","unstructured":"Moosmann B, Angerer V, Auw\u00e4rter V (2014) Inhomogeneities in herbal mixtures: a serious risk for consumers. Forensic Toxicol 33:54\u201360. https:\/\/doi.org\/10.1007\/s11419-014-0247-4","journal-title":"Forensic Toxicol"},{"key":"3146_CR9","doi-asserted-by":"publisher","first-page":"3937","DOI":"10.1007\/s00216-012-6560-z","volume":"405","author":"H Choi","year":"2013","unstructured":"Choi H, Heo S, Choe S et al (2013) Simultaneous analysis of synthetic cannabinoids in the materials seized during drug trafficking using GC-MS. Anal Bioanal Chem 405:3937\u20133944. https:\/\/doi.org\/10.1007\/s00216-012-6560-z","journal-title":"Anal Bioanal Chem"},{"key":"3146_CR10","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1093\/jat\/bkz028","volume":"44","author":"S Halter","year":"2020","unstructured":"Halter S, Mogler L, Auwarter V (2020) Quantification of herbal mixtures containing Cumyl-PEGACLONE-is inhomogeneity still an issue? J Anal Toxicol 44:81\u201385. https:\/\/doi.org\/10.1093\/jat\/bkz028","journal-title":"J Anal Toxicol"},{"key":"3146_CR11","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1093\/jat\/bks047","volume":"36","author":"KG Shanks","year":"2012","unstructured":"Shanks KG, Dahn T, Behonick G, Terrell A (2012) Analysis of first and second generation legal highs for synthetic cannabinoids and synthetic stimulants by ultra-performance liquid chromatography and time of flight mass spectrometry. J Anal Toxicol 36:360\u2013371. https:\/\/doi.org\/10.1093\/jat\/bks047","journal-title":"J Anal Toxicol"},{"key":"3146_CR12","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/dta.2237","volume":"10","author":"V Angerer","year":"2018","unstructured":"Angerer V, Mogler L, Steitz JP et al (2018) Structural characterization and pharmacological evaluation of the new synthetic cannabinoid CUMYL-PEGACLONE. Drug Test Anal 10:597\u2013603. https:\/\/doi.org\/10.1002\/dta.2237","journal-title":"Drug Test Anal"},{"key":"3146_CR13","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1002\/dta.2870","volume":"12","author":"L Janssens","year":"2020","unstructured":"Janssens L, Cannaert A, Connolly MJ, Liu H, Stove CP (2020) In vitro activity profiling of Cumyl-PEGACLONE variants at the CB(1) receptor: fluorination versus isomer exploration. Drug Test Anal 12:1336\u20131343. https:\/\/doi.org\/10.1002\/dta.2870","journal-title":"Drug Test Anal"},{"key":"3146_CR14","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1021\/acschemneuro.5b00107","volume":"6","author":"SD Banister","year":"2015","unstructured":"Banister SD, Stuart J, Kevin RC et al (2015) Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135. ACS Chem Neurosci 6:1445\u20131458. https:\/\/doi.org\/10.1021\/acschemneuro.5b00107","journal-title":"ACS Chem Neurosci"},{"key":"3146_CR15","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1007\/s11419-019-00514-w","volume":"38","author":"A Giorgetti","year":"2019","unstructured":"Giorgetti A, Mogler L, Halter S et al (2019) Four cases of death involving the novel synthetic cannabinoid 5F-Cumyl-PEGACLONE. Forensic Toxicol 38:314\u2013326. https:\/\/doi.org\/10.1007\/s11419-019-00514-w","journal-title":"Forensic Toxicol"},{"key":"3146_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12024-020-00334-0","volume":"17","author":"M Tiemensma","year":"2021","unstructured":"Tiemensma M, Rutherford JD, Scott T, Karch S (2021) Emergence of Cumyl-PEGACLONE-related fatalities in the Northern Territory of Australia. Forensic Sci Med Pathol 17:3\u20139. https:\/\/doi.org\/10.1007\/s12024-020-00334-0","journal-title":"Forensic Sci Med Pathol"},{"key":"3146_CR17","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00194-019-0338-y","volume":"29","author":"B Schmidt","year":"2019","unstructured":"Schmidt B, Nigbur S, Kegler R, B\u00fcttner A, Rentsch D (2019) Letale Intoxikation unter Beteiligung des neuen synthetischen cannabinoids 5F-Cumyl-PeGaClone. Rechtsmedizin 29:353. https:\/\/doi.org\/10.1007\/s00194-019-0338-y","journal-title":"Rechtsmedizin"},{"key":"3146_CR18","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s00414-023-02995-2","volume":"137","author":"O Groth","year":"2023","unstructured":"Groth O, Roider G, Angerer V et al (2023) \u201cSpice\u201d-related deaths in and around Munich, Germany: a retrospective look at the role of synthetic cannabinoid receptor agonists in our post-mortem cases over a seven-year period (2014\u20132020). Int J Legal Med 137:1059\u20131069. https:\/\/doi.org\/10.1007\/s00414-023-02995-2","journal-title":"Int J Legal Med"},{"key":"3146_CR19","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00414-017-1726-z","volume":"132","author":"M Falk","year":"2018","unstructured":"Falk M, Huhn R, Behmenburg F, Ritz-Timme S, Mayer F (2018) Biomechanical stress in myocardial infarctions: can endothelin-1 and growth differentiation factor 15 serve as immunohistochemical markers? Int J Legal Med 132:509\u2013518. https:\/\/doi.org\/10.1007\/s00414-017-1726-z","journal-title":"Int J Legal Med"},{"key":"3146_CR20","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1007\/s00414-020-02300-5","volume":"134","author":"A Gartz","year":"2020","unstructured":"Gartz A, Pawlik E, Eckhardt J, Ritz-Timme S, Huhn R, Mayer F (2020) Effects of cocaine and levamisole (as adulterant) on the isolated perfused Langendorff heart. Int J Legal Med 134:1741\u20131752. https:\/\/doi.org\/10.1007\/s00414-020-02300-5","journal-title":"Int J Legal Med"},{"key":"3146_CR21","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1177\/1039856216663733","volume":"24","author":"J Courts","year":"2016","unstructured":"Courts J, Maskill V, Gray A, Glue P (2016) Signs and symptoms associated with synthetic cannabinoid toxicity: systematic review. Australas Psychiatry 24:598\u2013601. https:\/\/doi.org\/10.1177\/1039856216663733","journal-title":"Australas Psychiatry"},{"key":"3146_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.brainresbull.2015.10.013","volume":"126","author":"HH Muller","year":"2016","unstructured":"Muller HH, Kornhuber J, Sperling W (2016) The behavioral profile of spice and synthetic cannabinoids in humans. Brain Res Bull 126:3\u20137. https:\/\/doi.org\/10.1016\/j.brainresbull.2015.10.013","journal-title":"Brain Res Bull"},{"key":"3146_CR23","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00213-013-3188-4","volume":"228","author":"M Spaderna","year":"2013","unstructured":"Spaderna M, Addy PH, D\u2019Souza DC (2013) Spicing things up: synthetic cannabinoids. Psychopharmacology (Berl) 228:525\u2013540. https:\/\/doi.org\/10.1007\/s00213-013-3188-4","journal-title":"Psychopharmacology (Berl)"},{"key":"3146_CR24","doi-asserted-by":"publisher","first-page":"93","DOI":"10.9740\/mhc.2019.03.093","volume":"9","author":"A Alipour","year":"2019","unstructured":"Alipour A, Patel PB, Shabbir Z, Gabrielson S (2019) Review of the many faces of synthetic cannabinoid toxicities. Ment Health Clin 9:93\u201399. https:\/\/doi.org\/10.9740\/mhc.2019.03.093","journal-title":"Ment Health Clin"},{"key":"3146_CR25","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s12012-019-09522-z","volume":"19","author":"HM Ozturk","year":"2019","unstructured":"Ozturk HM, Yetkin E, Ozturk S (2019) Synthetic cannabinoids and cardiac arrhythmia risk: review of the literature. Cardiovasc Toxicol 19:191\u2013197. https:\/\/doi.org\/10.1007\/s12012-019-09522-z","journal-title":"Cardiovasc Toxicol"},{"key":"3146_CR26","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/nrcardio.2017.130","volume":"15","author":"P Pacher","year":"2018","unstructured":"Pacher P, Steffens S, Hasko G, Schindler TH, Kunos G (2018) Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly. Nat Rev Cardiol 15:151\u2013166. https:\/\/doi.org\/10.1038\/nrcardio.2017.130","journal-title":"Nat Rev Cardiol"},{"key":"3146_CR27","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1089\/can.2020.0161","volume":"7","author":"P Yoganathan","year":"2022","unstructured":"Yoganathan P, Claridge H, Chester L, Englund A, Kalk NJ, Copeland CS (2022) Synthetic cannabinoid-related deaths in England, 2012\u20132019. Cannabis Cannabinoid Res 7:516\u2013525. https:\/\/doi.org\/10.1089\/can.2020.0161","journal-title":"Cannabis Cannabinoid Res"},{"key":"3146_CR28","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jemermed.2015.10.009","volume":"50","author":"J Von Der Haar","year":"2016","unstructured":"Von Der Haar J, Talebi S, Ghobadi F et al (2016) Synthetic cannabinoids and their effects on the cardiovascular system. J Emerg Med 50:258\u2013262. https:\/\/doi.org\/10.1016\/j.jemermed.2015.10.009","journal-title":"J Emerg Med"},{"key":"3146_CR29","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1177\/0269881117736918","volume":"32","author":"HM Ozturk","year":"2018","unstructured":"Ozturk HM, Erdogan M, Alsancak Y et al (2018) Electrocardiographic alterations in patients consuming synthetic cannabinoids. J Psychopharmacol 32:296\u2013301. https:\/\/doi.org\/10.1177\/0269881117736918","journal-title":"J Psychopharmacol"},{"key":"3146_CR30","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1039\/c6tx00259e","volume":"5","author":"J Yun","year":"2016","unstructured":"Yun J, Yoon KS, Lee TH et al (2016) Synthetic cannabinoid, JWH-030, induces QT prolongation through hERG channel inhibition. Toxicol Res (Camb) 5:1663\u20131671. https:\/\/doi.org\/10.1039\/c6tx00259e","journal-title":"Toxicol Res (Camb)"}],"container-title":["International Journal of Legal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00414-023-03146-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00414-023-03146-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00414-023-03146-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:05:45Z","timestamp":1712707545000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00414-023-03146-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,12]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["3146"],"URL":"https:\/\/doi.org\/10.1007\/s00414-023-03146-3","relation":{},"ISSN":["0937-9827","1437-1596"],"issn-type":[{"type":"print","value":"0937-9827"},{"type":"electronic","value":"1437-1596"}],"subject":[],"published":{"date-parts":[[2024,1,12]]},"assertion":[{"value":"27 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experiments were performed in accordance with the German legislation on protection of animals and the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85\u201323, revised 1996) and were approved by the local Animal Care and Use Committee of the University of Duesseldorf (project no. O 27\/12). The study did not include human participants or experiments with human tissues.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}